1.14
+0.02(+1.79%)
Currency In USD
| Previous Close | 1.12 |
| Open | 1.11 |
| Day High | 1.15 |
| Day Low | 1.11 |
| 52-Week High | 21.49 |
| 52-Week Low | 0.96 |
| Volume | 190,528 |
| Average Volume | 1.38M |
| Market Cap | 5.87M |
| PE | -0.21 |
| EPS | -5.33 |
| Moving Average 50 Days | 1.26 |
| Moving Average 200 Days | 2.12 |
| Change | 0.02 |
If you invested $1000 in Autonomix Medical, Inc. Common Stock (AMIX) since IPO date, it would be worth $11.24 as of September 17, 2025 at a share price of $1.14. Whereas If you bought $1000 worth of Autonomix Medical, Inc. Common Stock (AMIX) shares 6 months ago, it would be worth $572.86 as of September 17, 2025 at a share price of $1.14.
For more details, use our stock calculator to calculate how much you would've made investing different amounts on specific dates.
Autonomix Medical, Inc. Announces Abstract Accepted for Podium Presentation at the 2025 CIRSE Annual Congress
GlobeNewswire Inc.
Sep 09, 2025 1:00 PM GMT
Presentation to highlight findings from the first phase of the Company’s ongoing first-in-human proof-of-concept (PoC) clinical trial THE WOODLANDS, TX, Sept. 09, 2025 (GLOBE NEWSWIRE) -- Autonomix Medical, Inc. (NASDAQ: AMIX) (“Autonomix” or the “
Autonomix Medical, Inc. (NASDAQ: AMIX) Participates in Virtual Investor “What This Means” Segment
GlobeNewswire Inc.
Sep 04, 2025 1:00 PM GMT
Dr. Robert Schwartz, Chief Medical Officer of Autonomix, discusses the Company’s recently announced results from the post hoc analysis of its proof-of-concept human clinical trial (“PoC 1”) THE WOODLANDS, TX, Sept. 04, 2025 (GLOBE NEWSWIRE) -- Auto
Autonomix Medical, Inc. Demonstrates Sustained Pain Reduction, Quality of Life Gains and 100% Zero Opioid Use in Longer-Term Post Hoc Analysis from PoC 1 Study
GlobeNewswire Inc.
Sep 03, 2025 12:30 PM GMT
New longer-term post hoc analysis results of responders (n=6)1 showed long-lasting, durable pain reduction of nearly 66%, or a mean 5.08 reduction on the VAS pain scale, in patients with severe pancreatic cancer pain 100% of responders (n=7) 1 showed